Recombinant Mutant Human Tumor Necrosis Factor
Peritoneal Carcinomatosis
Explore 32 assets in Peritoneal Carcinomatosis →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05755685CT.gov Hyperthermic Intraperitoneal Treatment of rmhTNF for CRCPM: Phase II Clinical Trial | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Peritoneal Carcinomatosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Recombinant Mutant Human Tumor Necrosis Factor (this asset) | Second Affiliated Hospital, School of Medicine, Zhejiang University | P2 | CCC · 53 |
| Fluorouracilum | Ciusss de L'Est de l'Île de Montréal | P3 | BB |
| Irinotecan | Catharina Ziekenhuis Eindhoven | P3 | BB |
| Muamycin | H. Lee Moffitt Cancer Center and Research Institute | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P3 | BB |
| Oxaliplatin | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | P3 | BB |
| Capecitabine | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | P2/3 | BB |
| Indocyanine Green | Jules Bordet Institute | P2 | B |
| Sodium Thiosulfate | National Cancer Institute (NCI) | P2 | B |
+33 more in the Peritoneal Carcinomatosis cohort
Other indications for Recombinant Mutant Human Tumor Necrosis Factor
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Cancer | — | P2 | CC · 46 |
| Gastric Cancer | — | Unk | D · 28 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- FluorouracilumCiusss de L'Est de l'Île de MontréalBB
- IrinotecanCatharina Ziekenhuis EindhovenBB
- MuamycinH. Lee Moffitt Cancer Center and Research InstituteBB
- Cis-Diamminedichloroplatinum IiNational Cancer Institute (NCI)BB
- OxaliplatinDaping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityBB
Citation
Floatz Terminal. Recombinant Mutant Human Tumor Necrosis Factor in Peritoneal Carcinomatosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/recombinant-mutant-human-tumor-necrosis-factor-peritoneal-carcinomatosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →